Exicure Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Exicure.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Mar 10
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Exicure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:XCUR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20241-4-3-3N/A
6/30/20241-8-4-4N/A
3/31/20241-13-7-7N/A
12/31/2023N/A-17-10-10N/A
9/30/2023223-17-17N/A
6/30/2023243-22-22N/A
3/31/2023261-26-26N/A
12/31/202229-3-36-36N/A
9/30/20229-35-43-42N/A
6/30/20223-53-31-31N/A
3/31/20221-60-34-33N/A
12/31/20210-64-36-35N/A
9/30/2021-2-63-34-33N/A
6/30/20214-48-47-46N/A
3/31/20218-38-49-46N/A
12/31/202017-25-42-39N/A
9/30/202017-22-16-12N/A
6/30/202015-19-13-9N/A
3/31/202010-20-4-3N/A
12/31/20191-2601N/A
9/30/20191-21-20-20N/A
6/30/20191-21-19-19N/A
3/31/20190-22-19-19N/A
12/31/20180-22-20-19N/A
9/30/20182-21-19-19N/A
6/30/20185-18N/A-19N/A
3/31/20187-14N/A-17N/A
12/31/201710-11N/A-20N/A
9/30/20178-13N/A-9N/A
6/30/20176-15N/A-8N/A
3/31/20173-16N/A-8N/A
12/31/20161-17N/A-5N/A
12/31/20152-6N/A-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XCUR's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if XCUR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if XCUR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if XCUR's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if XCUR's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XCUR's Return on Equity is forecast to be high in 3 years time


Discover growth companies